Profile data is unavailable for this security.
About the company
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Its lead product candidates include LP-10, LP-310 and LP-410. LP-10 is the development name of its reformulation of tacrolimus specifically optimized for topical deposition to the internal surface of the urinary bladder lumen using a proprietary drug delivery platform. LP-310 is the development name of its oral, liposomal formulation of tacrolimus specifically optimized for local delivery to oral mucosa. It is also developing an oral, liposomal formulation of tacrolimus, LP-410, for the treatment of oral graft-versus-host disease (GVHD). LP-410 is an oral rinse, like LP-310, but has a different containment system. LP-410 targets the underlying mechanisms of oral GVHD, potentially providing a safe and effective treatment option for affected individuals.
- Revenue in USD (TTM)449.62k
- Net income in USD-4.62m
- Incorporated2005
- Employees5.00
- LocationLipella Pharmaceuticals Inc400 N Lexington St Ste Ll103PITTSBURGH 15208United StatesUSA
- Phone+1 (412) 901-0315
- Fax+1 (302) 658-3694
- Websitehttps://lipella.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MyMD Pharmaceuticals Inc | 0.00 | -7.07m | 5.39m | 9.00 | -- | 0.255 | -- | -- | -5.53 | -5.53 | 0.00 | 10.28 | 0.00 | -- | -- | 0.00 | -25.59 | -76.20 | -31.13 | -84.38 | -- | 7.64 | -- | -4,290.96 | -- | -- | 0.00 | -- | -- | -- | 49.15 | -- | -- | -- |
| Fresh Tracks Therapeutics Inc | 8.01m | -5.69m | 5.44m | 4.00 | -- | 0.5482 | -- | 0.68 | -1.38 | -1.38 | 1.49 | 1.66 | 0.7326 | -- | -- | 2,001,500.00 | -52.10 | -89.76 | -66.50 | -115.24 | -- | -- | -71.12 | -442.61 | -- | -1,272.00 | 0.00 | -- | 15.31 | 37.62 | 73.02 | -- | -- | -- |
| NLS Pharmaceutics AG | 0.00 | -15.47m | 5.51m | 2.00 | -- | -- | -- | -- | -0.534 | -0.534 | 0.00 | -0.1322 | 0.00 | -- | -- | 0.00 | -714.74 | -308.05 | -- | -- | -- | -- | -- | -- | -- | -175.42 | -- | -- | -- | -- | -38.08 | -- | -- | -- |
| Lipella Pharmaceuticals Inc | 449.62k | -4.62m | 5.57m | 5.00 | -- | 1.41 | -- | 12.38 | -0.7858 | -0.7858 | 0.0749 | 0.5194 | 0.0944 | -- | 6.16 | 89,924.00 | -96.96 | -- | -116.00 | -- | -- | -- | -1,027.31 | -- | -- | -- | 0.00 | -- | 144.15 | -- | -77.81 | -- | -- | -- |
| Halberd Corp | 281.24k | 25.34k | 5.60m | 3.00 | 3.79 | -- | 220.56 | 19.90 | 0.0023 | 0.0023 | 0.0018 | -0.0002 | 0.1449 | 0.0303 | 2.52 | -- | 1.31 | -- | 4.58 | -- | 50.00 | -- | 9.01 | -- | 0.2661 | 1.35 | 1.02 | -- | 271.52 | -- | -60.11 | -- | -- | -- |
| CeCors Inc | -100.00bn | -100.00bn | 5.61m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
| Emmaus Life Sciences Inc | 28.46m | -4.74m | 5.63m | 55.00 | -- | -- | -- | 0.1979 | -0.0931 | -0.0931 | 0.3905 | -0.6773 | 0.6349 | 0.8184 | 9.36 | 517,454.50 | -10.58 | -- | -- | -- | 93.69 | -- | -16.66 | -- | 0.1249 | 0.1426 | -- | -- | -10.77 | -- | 33.37 | -- | -- | -- |
| Soligenix Inc | 839.36k | -6.14m | 5.68m | 13.00 | -- | 1.64 | -- | 6.77 | -0.9164 | -0.9164 | 0.1085 | 0.243 | 0.0697 | -- | 5.86 | 64,566.15 | -51.01 | -75.40 | -872.23 | -154.32 | 11.59 | 22.83 | -731.60 | -620.02 | -- | -1,677.11 | 0.5639 | -- | -11.54 | -30.67 | 55.50 | -- | -- | -- |
| ProtoKinetix, Inc. | 0.00 | -415.48k | 5.69m | 0.00 | -- | 13.03 | -- | -- | -0.0012 | -0.0012 | 0.00 | 0.0013 | 0.00 | -- | -- | -- | -88.08 | -696.88 | -96.94 | -785.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 78.22 | -- | 10.78 | -- |
| Palisade Bio Inc | 250.00k | -12.30m | 5.71m | 9.00 | -- | 0.3667 | -- | 22.85 | -28.22 | -28.22 | 0.5485 | 18.30 | 0.0168 | -- | 0.3153 | 27,777.78 | -82.51 | -132.36 | -101.58 | -165.45 | -- | -- | -4,920.00 | -27,892.32 | -- | -856.33 | 0.0138 | -- | -- | -0.7814 | 13.74 | -- | 18.53 | -- |
| Hoth Therapeutics Inc | 0.00 | -7.85m | 5.72m | 2.00 | -- | 0.5772 | -- | -- | -2.44 | -2.44 | 0.00 | 2.03 | 0.00 | -- | -- | 0.00 | -96.38 | -157.07 | -110.40 | -177.32 | -- | -- | -- | -- | -- | -50.23 | 0.00 | -- | -- | -- | 31.01 | -- | -- | -- |
| Lixte Biotechnology Holdings Inc | 0.00 | -5.09m | 5.76m | 3.00 | -- | 11.64 | -- | -- | -2.77 | -2.77 | 0.00 | 1.78 | 0.00 | -- | -- | 0.00 | -103.09 | -104.18 | -111.07 | -111.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 19.41 | -- | -- | -- |
| First Wave BioPharma Inc | 0.00 | -16.10m | 5.77m | 15.00 | -- | 1.23 | -- | -- | -88.75 | -88.75 | 0.00 | 2.31 | 0.00 | -- | -- | 0.00 | -256.35 | -295.92 | -471.06 | -1,599.51 | -- | -- | -- | -- | -- | -790.91 | 0.1454 | -- | -- | -- | -7.55 | -- | -- | -- |
| HST Global Inc | 0.00 | -146.22k | 5.77m | 1.00 | -- | -- | -- | -- | -0.0279 | -0.0279 | 0.00 | -0.1128 | 0.00 | -- | -- | -- | -17,002.33 | -5,836.01 | -- | -- | -- | -- | -- | -- | -- | -26.54 | -- | -- | -- | -- | -0.7858 | -- | -- | -- |
| Burzynski Research Institute Inc | 0.00 | -1.19m | 5.78m | 2.00 | -- | -- | -- | -- | -0.009 | -0.009 | 0.00 | -0.0003 | 0.00 | -- | -- | -- | -84,895.00 | -10,098.54 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 6.18 | -- | -- | -- |
| Kintara Therapeutics Inc | 0.00 | -10.77m | 5.83m | 2.00 | -- | -- | -- | -- | -5.98 | -5.98 | 0.00 | -0.0157 | 0.00 | -- | -- | 0.00 | -179.36 | -220.94 | -316.27 | -329.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 40.24 | -- | 78.93 | -- |
Data as of May 13 2024. Currency figures normalised to Lipella Pharmaceuticals Inc's reporting currency: US Dollar USD
5.92%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Sabby Management LLCas of 31 Dec 2023 | 269.83k | 4.32% |
| Geode Capital Management LLCas of 31 Dec 2023 | 42.09k | 0.67% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 34.52k | 0.55% |
| Two Sigma Investments LPas of 31 Dec 2023 | 15.87k | 0.25% |
| Tower Research Capital LLCas of 31 Dec 2023 | 6.92k | 0.11% |
| UBS Securities LLCas of 31 Dec 2023 | 761.00 | 0.01% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 30.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
